IO Frontiers World 2019

The Phacilitate Blog

Bringing together news and articles


Immunotherapy company envisions an app store for the human body

In Seattle, Wash., the largest city in America’s Pacific Northwest and home to corporate giants in software and e-commerce, innovation must drip amidst all of the drops of rain that fall so predictably from its skies. Here Immusoft, a small gene therapy company, may be on the cusp of something that could one day have as much global impact as the offerings of its brand name neighbors....

Read more


Meeting Report: Lessons from the first ATMPs

24 September 2017: It is one thing to research and develop an advanced therapy medicinal product (ATMP), but quite another to bring it successfully to market. Among the nine ATMPs approved in Europe since 2009, only five are still on the market. The reasons for the slow commercial acceptance of these products were discussed at the Phacilitate cell and gene therapy conference in Berlin, Germany on 21 September 2017....

Read more


Computational Medicine in the Immuno-Oncology Age

The human body has established immunological processes to keep cancerous cell growth in check. In the late 1990’s, researchers began to identify mechanisms by which tumor cells could evade a patient’s immune system through selective gain-of-function gene mutations. While this was an important observation for how cancerous cells adapt and evolve in order to survive; it also provided a powerful...

Read more

The increasing popularity of cancer vaccines

Cancer vaccines have gained increasing popularity since the US FDA approved the first cancer vaccine, sipuleucel-T, in 2010 and then approved the active specific immunotherapeutic agent, ipilimumab, in 2011. Several other recently reported positive randomized trials have started...

Read more

Bioinformatic modelling for Immunotherapy

Precision medicine requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumour. Today, technological advances (e.g., next-generation sequencing) are providing unprecedented opportunities to draw...

Read more

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy